While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.